- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04828174
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
The Safety and Clinical Efficacy of Human TRBC1 CAR-T Cell Therapy for Patients With Relapsed/Refractory TRBC1 Positive T Cell Hematological Maliganacies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Xianmin Song
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
(1)18 to 70 Years Old, Male and female; (2) Expected survival > 12 weeks; (3) ECOG score 0-2; (4) Confirmed diagnosis of acute T cell leukemia and screened for TRBC1 positive, including following conditions:
- Patients who do not get a CR with ≥2 prior lines of therapy
- Those who achieves CR, but have a early relapse(<12months),or a late relapse (>=12months) failing to acheive a CR after 1 line salvage chemotherapy
- For any Patiens failed ASCT/allo-SCT (5) Relapsed and refractory patients with diagnosis of T cell lymphoma have had≥2 prior lines of therapy,including:
a. Peripheral T cell lymphoma NOS, or b. Angioimmunoblastic T cell lymphoma, or c. Anaplastic large cell lymphoma (6) Confirmed T lymphoblatic lymphoma
- Patients who do not get a CR with ≥2 prior lines of therapy
- Relapsed patients failing to acheive a CR after 1 line salvage chemotherapy
- For any Patiens failed ASCT/allo-SCT (7) The venous access required for collection can be established and mononuclear cell collection can be determined by the investigators; (8) Liver, kidney and cardiopulmonary functions meet the following requirements:
a. Ccr≥60mL/min(Cockcroft Gault) b. Left ventricular ejection fraction >50%; c. Baseline oxygen saturation>92%; d. Total bilirubin ≤ 1.5×ULN; e. ALT and AST ≤ 3×ULN; (9) Able to understand and sign the In
Exclusion Criteria:
- Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ after radical resection;
- Uncontrolled infection;patients with positive HBsAg or HBcAb and peripheral blood HBV DNA titer detection ≥ 1 × 10^2 copy number / L; HCV antibody positive and peripheral blood HCV RNA positive; HIV antibody positive; CMV DNA positive; syphilis positive;
- Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease;
- Any uncontrolled disease may affect entry
- Current or history of CNS involvement by malignancy.Known history or presence of clinically relevant central nervous system (CNS) pathology. Patients with a known history or prior diagnosis other immunologic or inflammatory disease affecting the CNS (such as epilepsy)
- Patients who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use); And subjects treated with systemic steroids (except inhalation or topical use) within 72h prior to cell transfusion;
- Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pr egnancy within 1 year after cell transfusion;
- Active or uncontrollable infection requiring systemic therapy
- Received CAR-T treatment or other gene therapies before enrollment;
- Kown be allergic to anti-TRBC1 CAR-T cells or drugs(Fludarabine or Cyclophophamide)
- The investigators consider other conditions unsuitable for enrollment.
- Patients who may not be able to sign the Informed Consent due to disease,or who do not understand or unwillingness or inability to comply with research requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: anti-TRBC1 CAR-T cell
Administration with anti-TRBC1 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients.
|
TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability
Time Frame: 28 days post infusion
|
Safety measured by occurence of study related adverse effects defined by NCI CTCAE5.0
|
28 days post infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CAR-T cell expansion and persistence
Time Frame: 2 years post infusion
|
To evaluate anti-TRBC1 CAR-T cell expansion and persistence after infusion
|
2 years post infusion
|
Total response rate (ORR) after administration
Time Frame: 3 months post infusion
|
CR+CRi for T-ALL CR+PR for T cell lyphoma
|
3 months post infusion
|
Duration of remission (DOR) after administration
Time Frame: 2 years post infusion
|
Duration of remission (DOR) after administration
|
2 years post infusion
|
Overall Survival (OS)after administration
Time Frame: 2 years post infusion
|
Overall Survival (OS)after administration
|
2 years post infusion
|
Progression Free Survival (PFS) after infusion
Time Frame: 2 years after infusion
|
Progression Free Survival (PFS) after infusion
|
2 years after infusion
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphoid
- Leukemia
- Lymphadenopathy
- Lymphoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Leukemia, T-Cell
- Immunoblastic Lymphadenopathy
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Other Study ID Numbers
- SHYSXY-202101-CART
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angioimmunoblastic T-cell Lymphoma
-
Navy General Hospital, BeijingChinese PLA General HospitalRecruitingRelapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell LymphomaChina
-
The Lymphoma Academic Research OrganisationCelgeneActive, not recruitingRelapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell LymphomaFrance, Denmark, United Kingdom, Austria, Belgium
-
Huijing WuBeijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical GroupRecruitingAngioimmunoblastic T-cell LymphomaChina
-
Sun Yat-sen UniversityNot yet recruitingAngioimmunoblastic T-cell LymphomaChina
-
Ruijin HospitalActive, not recruitingAngioimmunoblastic T-cell LymphomaChina
-
Peking Union Medical College HospitalBeijing Longfu HospitalNot yet recruitingAngioimmunoblastic T-cell LymphomaChina
-
University of NebraskaNational Cancer Institute (NCI); Spectrum Pharmaceuticals, IncCompletedPeripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell LymphomaUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedAnaplastic Large Cell Lymphoma, ALK-Positive | Hepatosplenic T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic Large Cell Lymphoma, ALK-Negative | Stage II Angioimmunoblastic T-cell Lymphoma | Stage II Enteropathy-Associated T-Cell Lymphoma | Stage III Angioimmunoblastic... and other conditionsUnited States
-
Qingdao UniversityUnknownAngioimmunoblastic T-cell LymphomaChina
-
Ou Bai, MD/PHDSecond Hospital of Jilin University; China-Japan Union Hospital, Jilin UniversityRecruitingAngioimmunoblastic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedChina
Clinical Trials on anti-TRBC1 CAR-T cell therapy
-
City of Hope Medical CenterNational Cancer Institute (NCI); California Institute for Regenerative Medicine...RecruitingBreast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the LeptomeningesUnited States
-
Fudan UniversityGuangzhou Bioresette Biomedical Technology Co., Ltd.; Chaosu Hu,Principal Investigator...RecruitingNasopharyngeal CarcinomaChina
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
National University Hospital, SingaporeRecruitingLymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | CAR T-Cell-Related Encephalopathy Syndrome | Refractory LeukemiaSingapore
-
National University Hospital, SingaporeRecruitingLymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | CAR T-Cell-Related Encephalopathy SyndromeSingapore
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Autolus LimitedEnrolling by invitationMultiple Myeloma | DLBCL | T Cell Lymphoma | Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy | ALL, Adult and PediatricUnited Kingdom
-
The First Affiliated Hospital of Soochow UniversityRecruitingB-cell Acute Lymphoblastic LeukemiaChina
-
Institute of Hematology & Blood Diseases Hospital...Juventas Cell Therapy Ltd.RecruitingAutoimmune Hemolytic Anemia | Autologous CD19 CAR-T | Failure of Three or More Lines of TherapyChina